Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-04

AUTHORS

O. G. Kolterman, S. Schwartz, C. Corder, B. Levy, L. Klaff, J. Peterson, A. Gottlieb

ABSTRACT

Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal. More... »

PAGES

492-499

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00400683

DOI

http://dx.doi.org/10.1007/bf00400683

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010562990

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8778001


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amyloid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Analysis of Variance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Islet Amyloid Polypeptide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kolterman", 
        "givenName": "O. G.", 
        "id": "sg:person.0612636740.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612636740.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes & Glandular Disease Clinic", 
          "id": "https://www.grid.ac/institutes/grid.418418.0", 
          "name": [
            "Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "S.", 
        "id": "sg:person.012101272322.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012101272322.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oklahoma Medical Research Foundation", 
          "id": "https://www.grid.ac/institutes/grid.274264.1", 
          "name": [
            "Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corder", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Medical Research Corporation, Hartford, Connecticut, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Levy", 
        "givenName": "B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ranier Clinical Research Center, Renton, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klaff", 
        "givenName": "L.", 
        "id": "sg:person.0735444751.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735444751.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "J.", 
        "id": "sg:person.01301636770.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301636770.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottlieb", 
        "givenName": "A.", 
        "id": "sg:person.0673343117.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673343117.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1073/pnas.85.20.7763", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006142362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.84.23.8628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010355010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(92)90785-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010789135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(92)90785-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010789135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci111519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015733242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(86)90708-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016165956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198303033080903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021145684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1651-2227.1993.tb12669.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023585236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.39.6.752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033145490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.240550003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036886307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.240550003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036886307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.39.5.639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041468733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/joe.0.124r009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042042276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-2007-1003759", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057478338"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.78.5.1257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064297443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.78.5.8175987", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064318706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/mend-3-11-1775", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064330414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.28.12.1039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070733421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.18.8.1179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070746815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079958582", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080356418", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081993197", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082450201", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082740325", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-04", 
    "datePublishedReg": "1996-04-01", 
    "description": "Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00400683", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM", 
    "pagination": "492-499", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3252901627ef80593d7e9bbd60a7c4020110b8e934dce87abdc1a87604b62fa7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8778001"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00400683"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010562990"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00400683", 
      "https://app.dimensions.ai/details/publication/pub.1010562990"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130829_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00400683"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      74 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00400683 schema:about N1b249a10504344618497179e9bf75763
2 N2779339aa776422086c002ccd10f0864
3 N3cdedeff7bd243219436d37b70109c62
4 N4f197e1862d14cfda7256c512c62b8b7
5 N5538d6738a6a4dd9a13edf9da8ec56ac
6 N6c26b9a3c47249d6990f2cfc90fc0b75
7 N7e0d69373ade41dc8b6c637ddcd160b6
8 N7f766dd6ab534afd95f3523b117f4ced
9 N82e914e63d494c06b90649328c5bbc51
10 N92f2cb04418a4a648d58f23837d6d0df
11 Naebc702fb3a44e75b327140785eb019b
12 Naff624ee84564956b05b139287603901
13 Nb6c19e032dc645789e13cd22ebe85a6f
14 Nb983d56329da46269240700b90c60db1
15 Nba4216c34d604ae0855a1c58d61c0e2e
16 Nbdc06798ddb644da80d4f56b4a9e621c
17 Nd0ccafb1c22e48718d0949d946e24c0a
18 Nfd7836168be74d789dd170f06aa29d28
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author N65aadfcd490c4605a5acfdd25f260140
22 schema:citation sg:pub.10.1007/bf00400094
23 sg:pub.10.1007/bf00400569
24 sg:pub.10.1007/bf00401833
25 sg:pub.10.1007/bf00403371
26 sg:pub.10.1007/bf00404025
27 https://app.dimensions.ai/details/publication/pub.1079958582
28 https://app.dimensions.ai/details/publication/pub.1080356418
29 https://app.dimensions.ai/details/publication/pub.1081993197
30 https://app.dimensions.ai/details/publication/pub.1082450201
31 https://app.dimensions.ai/details/publication/pub.1082740325
32 https://doi.org/10.1002/jcb.240550003
33 https://doi.org/10.1016/0006-291x(86)90708-4
34 https://doi.org/10.1016/0140-6736(92)90785-2
35 https://doi.org/10.1055/s-2007-1003759
36 https://doi.org/10.1056/nejm198303033080903
37 https://doi.org/10.1073/pnas.84.23.8628
38 https://doi.org/10.1073/pnas.85.20.7763
39 https://doi.org/10.1111/j.1651-2227.1993.tb12669.x
40 https://doi.org/10.1172/jci111519
41 https://doi.org/10.1210/jc.78.5.1257
42 https://doi.org/10.1210/jcem.78.5.8175987
43 https://doi.org/10.1210/mend-3-11-1775
44 https://doi.org/10.1677/joe.0.124r009
45 https://doi.org/10.2337/diab.28.12.1039
46 https://doi.org/10.2337/diab.39.5.639
47 https://doi.org/10.2337/diab.39.6.752
48 https://doi.org/10.2337/diacare.18.8.1179
49 schema:datePublished 1996-04
50 schema:datePublishedReg 1996-04-01
51 schema:description Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree false
55 schema:isPartOf N31e6312921a1422bbccb665f8e49cc5c
56 N69bd4a82a5a44ad2b16fba04aa076f6f
57 sg:journal.1001482
58 schema:name Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM
59 schema:pagination 492-499
60 schema:productId N3a3086bb92c946a1a587f8b26ac24c47
61 N7ac12d603477420db7a6e956db1575da
62 N7cd4428b273647b7970716489ca2e782
63 N83c0e63eeff44b72b5517850ce293592
64 Nf04a840349b748d3b47b900b82ea98f4
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010562990
66 https://doi.org/10.1007/bf00400683
67 schema:sdDatePublished 2019-04-11T14:00
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher N5f9cfaf7e3e342b08f50b4edd094db38
70 schema:url http://link.springer.com/10.1007/BF00400683
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N0d8f344bddac4e3091e603b1858b84d2 schema:name Ranier Clinical Research Center, Renton, Washington, USA
75 rdf:type schema:Organization
76 N112ce5dd632b4814bc2c0cc3e734478d rdf:first N2e34580a291b4678a95f8a2d98eb747e
77 rdf:rest N2557a85bc34e4481999fdd1ce34aabaf
78 N1b249a10504344618497179e9bf75763 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Insulin
80 rdf:type schema:DefinedTerm
81 N2557a85bc34e4481999fdd1ce34aabaf rdf:first N611932f2f2f4483a824ad14122ea2c30
82 rdf:rest N6cc6b512ddcf4da28a37010d37f57791
83 N2779339aa776422086c002ccd10f0864 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Amyloid
85 rdf:type schema:DefinedTerm
86 N2e34580a291b4678a95f8a2d98eb747e schema:affiliation https://www.grid.ac/institutes/grid.274264.1
87 schema:familyName Corder
88 schema:givenName C.
89 rdf:type schema:Person
90 N31e6312921a1422bbccb665f8e49cc5c schema:volumeNumber 39
91 rdf:type schema:PublicationVolume
92 N3a3086bb92c946a1a587f8b26ac24c47 schema:name doi
93 schema:value 10.1007/bf00400683
94 rdf:type schema:PropertyValue
95 N3cdedeff7bd243219436d37b70109c62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Infusions, Intravenous
97 rdf:type schema:DefinedTerm
98 N4f197e1862d14cfda7256c512c62b8b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Placebos
100 rdf:type schema:DefinedTerm
101 N5538d6738a6a4dd9a13edf9da8ec56ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Diabetes Mellitus, Type 1
103 rdf:type schema:DefinedTerm
104 N5f9cfaf7e3e342b08f50b4edd094db38 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N611932f2f2f4483a824ad14122ea2c30 schema:affiliation N77295d5a279c4386ad79295d05fa498b
107 schema:familyName Levy
108 schema:givenName B.
109 rdf:type schema:Person
110 N65aadfcd490c4605a5acfdd25f260140 rdf:first sg:person.0612636740.83
111 rdf:rest N9042dcd7bb2c4d979e51d3edf31a1b3a
112 N69bd4a82a5a44ad2b16fba04aa076f6f schema:issueNumber 4
113 rdf:type schema:PublicationIssue
114 N6c26b9a3c47249d6990f2cfc90fc0b75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Adolescent
116 rdf:type schema:DefinedTerm
117 N6cc6b512ddcf4da28a37010d37f57791 rdf:first sg:person.0735444751.15
118 rdf:rest Nffde0892794c42c9aa4ce330e6ee6278
119 N77295d5a279c4386ad79295d05fa498b schema:name National Medical Research Corporation, Hartford, Connecticut, USA
120 rdf:type schema:Organization
121 N7ac12d603477420db7a6e956db1575da schema:name nlm_unique_id
122 schema:value 0006777
123 rdf:type schema:PropertyValue
124 N7cd4428b273647b7970716489ca2e782 schema:name dimensions_id
125 schema:value pub.1010562990
126 rdf:type schema:PropertyValue
127 N7e0d69373ade41dc8b6c637ddcd160b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Hypoglycemic Agents
129 rdf:type schema:DefinedTerm
130 N7f766dd6ab534afd95f3523b117f4ced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Middle Aged
132 rdf:type schema:DefinedTerm
133 N82e914e63d494c06b90649328c5bbc51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 N83c0e63eeff44b72b5517850ce293592 schema:name pubmed_id
137 schema:value 8778001
138 rdf:type schema:PropertyValue
139 N9042dcd7bb2c4d979e51d3edf31a1b3a rdf:first sg:person.012101272322.91
140 rdf:rest N112ce5dd632b4814bc2c0cc3e734478d
141 N92f2cb04418a4a648d58f23837d6d0df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Dose-Response Relationship, Drug
143 rdf:type schema:DefinedTerm
144 Nad6130caa7124d1cb628579aa3603884 rdf:first sg:person.0673343117.64
145 rdf:rest rdf:nil
146 Naebc702fb3a44e75b327140785eb019b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Male
148 rdf:type schema:DefinedTerm
149 Naff624ee84564956b05b139287603901 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adult
151 rdf:type schema:DefinedTerm
152 Nb6c19e032dc645789e13cd22ebe85a6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Female
154 rdf:type schema:DefinedTerm
155 Nb983d56329da46269240700b90c60db1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Analysis of Variance
157 rdf:type schema:DefinedTerm
158 Nba4216c34d604ae0855a1c58d61c0e2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Blood Glucose
160 rdf:type schema:DefinedTerm
161 Nbdc06798ddb644da80d4f56b4a9e621c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Islet Amyloid Polypeptide
163 rdf:type schema:DefinedTerm
164 Nd0ccafb1c22e48718d0949d946e24c0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Eating
166 rdf:type schema:DefinedTerm
167 Nf04a840349b748d3b47b900b82ea98f4 schema:name readcube_id
168 schema:value 3252901627ef80593d7e9bbd60a7c4020110b8e934dce87abdc1a87604b62fa7
169 rdf:type schema:PropertyValue
170 Nfd7836168be74d789dd170f06aa29d28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Injections, Subcutaneous
172 rdf:type schema:DefinedTerm
173 Nffde0892794c42c9aa4ce330e6ee6278 rdf:first sg:person.01301636770.40
174 rdf:rest Nad6130caa7124d1cb628579aa3603884
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
179 schema:name Clinical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1001482 schema:issn 0012-186X
182 1432-0428
183 schema:name Diabetologia
184 rdf:type schema:Periodical
185 sg:person.012101272322.91 schema:affiliation https://www.grid.ac/institutes/grid.418418.0
186 schema:familyName Schwartz
187 schema:givenName S.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012101272322.91
189 rdf:type schema:Person
190 sg:person.01301636770.40 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
191 schema:familyName Peterson
192 schema:givenName J.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301636770.40
194 rdf:type schema:Person
195 sg:person.0612636740.83 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
196 schema:familyName Kolterman
197 schema:givenName O. G.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612636740.83
199 rdf:type schema:Person
200 sg:person.0673343117.64 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
201 schema:familyName Gottlieb
202 schema:givenName A.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673343117.64
204 rdf:type schema:Person
205 sg:person.0735444751.15 schema:affiliation N0d8f344bddac4e3091e603b1858b84d2
206 schema:familyName Klaff
207 schema:givenName L.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735444751.15
209 rdf:type schema:Person
210 sg:pub.10.1007/bf00400094 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052810677
211 https://doi.org/10.1007/bf00400094
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/bf00400569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019893221
214 https://doi.org/10.1007/bf00400569
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/bf00401833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010472397
217 https://doi.org/10.1007/bf00401833
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/bf00403371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009939773
220 https://doi.org/10.1007/bf00403371
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/bf00404025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031992201
223 https://doi.org/10.1007/bf00404025
224 rdf:type schema:CreativeWork
225 https://app.dimensions.ai/details/publication/pub.1079958582 schema:CreativeWork
226 https://app.dimensions.ai/details/publication/pub.1080356418 schema:CreativeWork
227 https://app.dimensions.ai/details/publication/pub.1081993197 schema:CreativeWork
228 https://app.dimensions.ai/details/publication/pub.1082450201 schema:CreativeWork
229 https://app.dimensions.ai/details/publication/pub.1082740325 schema:CreativeWork
230 https://doi.org/10.1002/jcb.240550003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036886307
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/0006-291x(86)90708-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016165956
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/0140-6736(92)90785-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010789135
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1055/s-2007-1003759 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057478338
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1056/nejm198303033080903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021145684
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1073/pnas.84.23.8628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010355010
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1073/pnas.85.20.7763 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006142362
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1111/j.1651-2227.1993.tb12669.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023585236
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1172/jci111519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015733242
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1210/jc.78.5.1257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064297443
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1210/jcem.78.5.8175987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064318706
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1210/mend-3-11-1775 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064330414
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1677/joe.0.124r009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042042276
255 rdf:type schema:CreativeWork
256 https://doi.org/10.2337/diab.28.12.1039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070733421
257 rdf:type schema:CreativeWork
258 https://doi.org/10.2337/diab.39.5.639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041468733
259 rdf:type schema:CreativeWork
260 https://doi.org/10.2337/diab.39.6.752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033145490
261 rdf:type schema:CreativeWork
262 https://doi.org/10.2337/diacare.18.8.1179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070746815
263 rdf:type schema:CreativeWork
264 https://www.grid.ac/institutes/grid.274264.1 schema:alternateName Oklahoma Medical Research Foundation
265 schema:name Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
268 schema:name Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.418418.0 schema:alternateName Diabetes & Glandular Disease Clinic
271 schema:name Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...